[Ocular involvement in connective tissue diseases and vasculitides].
Connective tissue diseases and systemic vasculitides are commonly associated with ocular manifestations, which can lead to severe complications and even blindness. The present review article describes these ocular manifestations, their signs and symptoms and possible treatment options for Sjoegren's syndrome, systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APLS), as well as those of giant cell arteritis/cranial arteritis, ANCA-associated vasculitides and Behçet's disease. Additionally, possible ocular adverse effects of antimalarial agents are described.
Deuter
C
C
Department für Augenheilkunde, Universitätsklinikum Tübingen, Schleichstrassse 12-16, Tübingen, Germany. christoph.deuter@med.uni-tuebingen.de
Kötter
I
I
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects; D001688:Biological Products / Q000008:administration & dosage / Q000009:adverse effects; D001766:Blindness / Q000209:etiology / Q000517:prevention & control; D003240:Connective Tissue Diseases / Q000175:diagnosis* / Q000188:drug therapy; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005128:Eye Diseases / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D008134:Long-Term Care; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D014657:Vasculitis / Q000175:diagnosis* / Q000188:drug therapy
D000305:Adrenal Cortex Hormones; D001688:Biological Products; D007166:Immunosuppressive Agents; D011239:Prednisolone